Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements study observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://paulf190lbw0.anchor-blog.com/profile